Poxel SA
7PO
Company Profile
Business description
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
Contact
259/261 Avenue Jean Jaures
Immeuble le Sunway
Lyon69007
FRAT: +33 437372010
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
3 ASX opportunities after earnings season
Uncovering key opportunities following February’s results.
stocks
Oracle earnings: Solid execution secures revenue target and mitigates investor concerns
We raise our fair value estimate for Oracle stock.
stocks
US dividend shares are getting a boost from the HALO trade. Can it last?
Both high-dividend stocks and dividend-growth stocks are outperforming amid AI disruption.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,786.00 | 8.80 | -0.10% |
| CAC 40 | 7,911.53 | 145.83 | -1.81% |
| DAX 40 | 23,447.29 | 142.36 | -0.60% |
| Dow JONES (US) | 46,558.47 | 119.38 | -0.26% |
| FTSE 100 | 10,261.15 | 44.00 | -0.43% |
| HKSE | 25,522.66 | 57.06 | 0.22% |
| NASDAQ | 22,105.36 | 206.62 | -0.93% |
| Nikkei 225 | 53,138.42 | 681.19 | -1.27% |
| NZX 50 Index | 13,161.71 | 25.63 | -0.19% |
| S&P 500 | 6,632.19 | 40.43 | -0.61% |
| S&P/ASX 200 | 8,573.60 | 2.00 | -0.02% |
| SSE Composite Index | 4,059.58 | 35.87 | -0.88% |